Oral rotavirus vaccination in breast- and bottle-fed infants aged 6 to 12 months
- PMID: 3019074
- DOI: 10.1111/j.1651-2227.1986.tb10253.x
Oral rotavirus vaccination in breast- and bottle-fed infants aged 6 to 12 months
Abstract
Oral bovine rotavirus vaccine RIT 4237 was tested at two dose levels in 217 children between 6 and 12 months of age who received either breast milk or bottle milk (cow's milk or infant formula) before vaccination. Of the children 65% were initially seronegative for rotavirus ELISA IgG and IgM antibody. The full vaccine dose (10(8.3) 50% tissue culture infective doses, TCID50) induced seroconversion rates 81% and 86% and booster response rates 69% and 64% in breast and bottle-fed children, respectively. There was no difference in the vaccine response of infants receiving cow's milk or infant formula either. It is concluded that the RIT 4237 rotavirus vaccine at the dose level 10(8.3) TCID50 gives a satisfactory response in both breast- and bottle-fed children in this age group, but multiple vaccinations may be needed for maximal efficacy.
Similar articles
-
Dose-response study of RIT 4237 oral rotavirus vaccine in breast-fed and formula-fed infants.Pediatr Infect Dis. 1985 Nov-Dec;4(6):622-5. doi: 10.1097/00006454-198511000-00005. Pediatr Infect Dis. 1985. PMID: 3001659
-
Response to RIT 4237 oral rotavirus vaccine in breast-fed and formula-fed infants.Helv Paediatr Acta. 1986 Aug;41(3):203-8. Helv Paediatr Acta. 1986. PMID: 3019954
-
Response to RIT 4237 oral rotavirus vaccine in human milk, adapted-and soy-formula fed infants.Acta Paediatr Scand. 1989 Sep;78(5):759-62. doi: 10.1111/j.1651-2227.1989.tb11139.x. Acta Paediatr Scand. 1989. PMID: 2556883 Clinical Trial.
-
Effect of dose and a comparison of measures of vaccine take for oral rhesus rotavirus vaccine. The Maryland Clinical Studies Group.Pediatr Infect Dis J. 1990 May;9(5):339-44. doi: 10.1097/00006454-199005000-00007. Pediatr Infect Dis J. 1990. PMID: 2162027 Clinical Trial.
-
Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines.J Infect Dis. 1996 Sep;174 Suppl 1:S107-11. doi: 10.1093/infdis/174.supplement_1.s107. J Infect Dis. 1996. PMID: 8752299 Review.
Cited by
-
A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simultaneously with or without the buffering agent in healthy infants in India.Hum Vaccin Immunother. 2018 Jul 3;14(7):1791-1799. doi: 10.1080/21645515.2018.1450709. Epub 2018 Apr 12. Hum Vaccin Immunother. 2018. PMID: 29543547 Free PMC article. Clinical Trial.
-
Rotavirus-specific intestinal immune response in mice assessed by enzyme-linked immunospot assay and intestinal fragment culture.Clin Diagn Lab Immunol. 1994 Nov;1(6):722-8. doi: 10.1128/cdli.1.6.722-728.1994. Clin Diagn Lab Immunol. 1994. PMID: 8556527 Free PMC article.
-
Rotavirus vaccine for preventing diarrhoea.Cochrane Database Syst Rev. 2004;2004(1):CD002848. doi: 10.1002/14651858.CD002848.pub2. Cochrane Database Syst Rev. 2004. PMID: 14973994 Free PMC article.
-
Rotaviruses: immunological determinants of protection against infection and disease.Adv Virus Res. 1994;44:161-202. doi: 10.1016/s0065-3527(08)60329-2. Adv Virus Res. 1994. PMID: 7817873 Free PMC article. Review.
-
Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.Vaccines (Basel). 2020 Jun 27;8(3):341. doi: 10.3390/vaccines8030341. Vaccines (Basel). 2020. PMID: 32604982 Free PMC article. Review.